Domov › Crohnova choroba › Ohio
Klinické štúdie Crohnova choroba v štáte Ohio
30 štúdií pre Crohnova choroba hľadá účastníkov v zariadeniach v štáte Ohio.
Mestá v štáte Ohio
Oficiálny text štúdie (anglicky)
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- Great Lakes Gastroenterology Research, LLC ( Site 5016), Mentor
Prebieha náborFáza 3
Vek 16 až 80 · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT06430801Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Gastro Intestinal Research Institute of Northern Ohio /ID# 283860, Westlake
Prebieha náborFáza 2
Vek 18 až 75 · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT07697456Investigating the Effect of the Non-nutritive Sweetener Sucralose in Inflammatory Bowel Disease
- UH Minoff Health Center, Chagrin Falls
- University Hospitals Cleveland Medical Center, Cleveland
- UH Westlake Health Center, Westlake
Prebieha náborVítaní zdravých dobrovoľníkov
Vek 18 až 75 · Všetky pohlavia · Aktualizované 1. 10. 2026 · NCT07852273A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Gastro Health Research - Cincinnati, Cincinnati
- DSI Research Northridge LLC, Dayton
- Gastro Health Research - Liberty Township, Liberty Township
- a 3 ďalších
Prebieha náborFáza 4
Vek 18 až 80 · Všetky pohlavia · Aktualizované 30. 9. 2026 · NCT06581328Non-nutritive Sweeteners in Inflammatory Bowel Disease
- UH Minoff Health Center, Chagrin Falls
- University Hospitals Cleveland Medical Center, Cleveland
- UH Westlake Health Center, Westlake
Prebieha náborVítaní zdravých dobrovoľníkov
Vek 18 až 70 · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT07769437Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- University of Cincinnati /ID# 265589, Cincinnati
- The Ohio State University /ID# 265577, Columbus
Prebieha náborFáza 2
Vek 18 až 75 · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT06548542A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
- Great Lakes Gastroenterology Research, LLC, Mentor
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT07499232A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
- Cincinnati Children's Hospital Medical Center, Cincinnati
Prebieha náborFáza 3
Vek 3 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT06663332A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
- Great Lakes Gastroenterology Research, LLC, Mentor
Prebieha náborFáza 2
Vek 18 až 75 · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT06233461Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Gastro Intestinal Research Institute of Northern Ohio, LLC, Westlake
Prebieha náborFáza 3
Vek 18 až 70 · Všetky pohlavia · Aktualizované 24. 9. 2026 · NCT06937099Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Ohio State University Comprehensive Cancer Center, Columbus
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 23. 9. 2026 · NCT03816345An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Gastroenterology & Hepatology Specialists, Inc.-Site nUmber: 8400139, Canton
- University Hospitals Cleveland Medical Center-Site Number: 8400073, Cleveland
- Ohio Gastroenterology Group Inc.-8400006, Columbus
- a 5 ďalších
Prebieha náborFáza 3
Vek 16 až 80 · Všetky pohlavia · Aktualizované 23. 9. 2026 · NCT07184931A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Ohio Gastroenterology Group Inc.-Site Number: 8400006, Columbus
- Medical Associates Research Group-Site Number: 8400063, Columbus
- OSU Wexner Medical Center-Site Number: 8400077, Columbus
- a 1 ďalších
Prebieha náborFáza 3
Vek 16 až 80 · Všetky pohlavia · Aktualizované 23. 9. 2026 · NCT07184944A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
- Cleveland Clinic - Cleveland /ID# 256453, Cleveland
Prebieha náborFáza 3
Vek 2 až 17 · Všetky pohlavia · Aktualizované 23. 9. 2026 · NCT05995353A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- University of Cincinnati, Cincinnati
- Ohio Gastroenterology group, Inc., Columbus
- Great Lakes Gastroenterology Research, LLC, Mentor
- a 1 ďalších
Prebieha náborFáza 4
Vek 18 až 70 · Všetky pohlavia · Aktualizované 9. 9. 2026 · NCT06045754A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
- Great Lakes Gastroenterology Research, LLC, Mentor
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 28. 8. 2026 · NCT07577843Ultrasound-Guided Versus Standard Margin Selection in Ileocecal Resection of Terminal Ileal CD
- Cleveland Clinic, Cleveland
Prebieha nábor
Vek 18 a viac · Všetky pohlavia · Aktualizované 27. 8. 2026 · NCT07680283A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
- Childrens Medical Center, Dayton
Prebieha náborFáza 3
Vek 2 až 17 · Všetky pohlavia · Aktualizované 24. 8. 2026 · NCT05509777Zymfentra (Infliximab-dyyb) REal World Cohort STudy
- University of Cincinnati, Cincinnati
Prebieha náborObservačná štúdia
Vek 18 a viac · Všetky pohlavia · Aktualizované 5. 8. 2026 · NCT07237516Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
- UH Cleveland Medical Center /ID# 262188, Cleveland
Prebieha náborFáza 3
Vek 2 až 17 · Všetky pohlavia · Aktualizované 24. 6. 2026 · NCT06332534A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- University Children's Clinic, Cleveland
- Cleveland Clinic, Cleveland
Prebieha náborFáza 3
Vek 2 až 17 · Všetky pohlavia · Aktualizované 22. 6. 2026 · NCT06405087Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
- Cincinnati Children's Hospital Medical Center, Cincinnati
- UH/Rainbow Babies and Children's Hospital, Cleveland
- Nationwide Children's Hospital, Columbus
Prebieha náborFáza 4
Vek 6 až 17 · Všetky pohlavia · Aktualizované 27. 5. 2026 · NCT05781152A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- University Hospitals Cleveland Medical Center - 11100 Euclid Ave, Cleveland
Prebieha náborFáza 3
Vek 2 a viac · Všetky pohlavia · Aktualizované 7. 5. 2026 · NCT05442567Precise Infliximab Exposure and Pharmacodynamic Control
- Cincinnati Children's Hospital, Cincinnati
- Cleveland Clinic Children's Hospital, Cleveland
- Nationwide Children's Hospital, Columbus
Prebieha náborFáza 2/3
Vek 6 až 22 · Všetky pohlavia · Aktualizované 5. 5. 2026 · NCT05660746A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
- University Hospitals Cleveland Medical Center, Cleveland
Prebieha náborFáza 3
Vek 2 až 17 · Všetky pohlavia · Aktualizované 5. 5. 2026 · NCT04779320Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
- OSU Inflammatory Bowel Disease Center, Hilliard
Prebieha náborFáza 2
Vek 18 až 75 · Všetky pohlavia · Aktualizované 27. 4. 2026 · NCT06456593A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Cincinnati
- Mirador Therapeutics Selected Site, Liberty Township
Prebieha náborFáza 2
Vek 18 až 80 · Všetky pohlavia · Aktualizované 12. 3. 2026 · NCT07113522Treatment of Moderate to Severe Refractory Crohn's Disease
- Cleveland Clinic, Cleveland
Prebieha náborFáza 1/2
Vek 18 až 65 · Všetky pohlavia · Aktualizované 10. 12. 2025 · NCT06721962Evaluation of the SMART IBD App in Pediatric IBD
- Cincinnati Children's Hospital Medical Center, Cincinnati
Prebieha nábor
Vek 13 až 17 · Všetky pohlavia · Aktualizované 21. 11. 2025 · NCT07195123Development of a Novel Endoscopic Index and Patient-reported Outcome Measure for Clinical Trials in Participants With Permanent Ileostomy
- Cleveland Clinic Foundation, Cleveland
Prebieha náborObservačná štúdia
Vek 18 a viac · Všetky pohlavia · Aktualizované 12. 11. 2025 · NCT06670638Z ClinicalTrials.gov, dáta načítané 5. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.